NASDAQ:BBNX Beta Bionics (BBNX) Stock Price, News & Analysis $17.05 +0.16 (+0.95%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Beta Bionics Stock (NASDAQ:BBNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Beta Bionics alerts:Sign Up Key Stats Today's Range$16.69▼$18.3350-Day Range$12.53▼$19.4552-Week Range$8.89▼$24.50Volume892,018 shsAverage Volume784,221 shsMarket Capitalization$741.16 millionP/E RatioN/ADividend YieldN/APrice Target$22.56Consensus RatingModerate Buy Company Overview Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA. Read More Beta Bionics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreBBNX MarketRank™: Beta Bionics scored higher than 53% of companies evaluated by MarketBeat, and ranked 528th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBeta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageBeta Bionics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beta Bionics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBeta Bionics has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BBNX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeta Bionics does not currently pay a dividend.Dividend GrowthBeta Bionics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BBNX. News and Social Media2.5 / 5News Sentiment0.44 News SentimentBeta Bionics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Beta Bionics this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $444,376.00 in company stock.Read more about Beta Bionics' insider trading history. Receive BBNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address BBNX Stock News HeadlinesStephen Feider Sells 5,587 Shares of Beta Bionics (NASDAQ:BBNX) StockAugust 21 at 8:32 AM | insidertrades.comBeta Bionics, Inc. to Present at Upcoming Healthcare Investor Conferences in September 2025August 21 at 8:31 AM | quiverquant.comQThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. | Weiss Ratings (Ad)Beta Bionics Announces Participation at Upcoming Investor ConferencesAugust 21 at 8:00 AM | globenewswire.comBeta Bionics, Inc. (NASDAQ:BBNX) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 18, 2025 | americanbankingnews.comBeta Bionics Reports Record Growth in Earnings CallAugust 1, 2025 | msn.comBeta Bionics, Inc. (BBNX) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comBeta Bionics, Inc. 2025 Q2 - Results - Earnings Call PresentationJuly 31, 2025 | seekingalpha.comSee More Headlines BBNX Stock Analysis - Frequently Asked Questions How have BBNX shares performed this year? Beta Bionics' stock was trading at $23.81 at the beginning of the year. Since then, BBNX stock has decreased by 28.4% and is now trading at $17.05. How were Beta Bionics' earnings last quarter? Beta Bionics, Inc. (NASDAQ:BBNX) announced its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.12. The company earned $23.24 million during the quarter, compared to the consensus estimate of $19.73 million. Read the conference call transcript. When did Beta Bionics IPO? Beta Bionics (BBNX) raised $204 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at $17.00 per share. When did Beta Bionics' lock-up period expire? Beta Bionics's lock-up period expired on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its public offering on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Since the end of Beta Bionics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Beta Bionics' major shareholders? Top institutional investors of Beta Bionics include Eventide Asset Management LLC (11.35%), Soleus Capital Management L.P. (8.79%), Sands Capital Alternatives LLC (8.21%) and Divisadero Street Capital Management LP (2.18%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider and Mark Hopman. View institutional ownership trends. How do I buy shares of Beta Bionics? Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BBNX Previous SymbolNASDAQ:BBNX CIK1674632 WebN/A Phone(949) 427-7785FaxN/AEmployees294Year FoundedN/APrice Target and Rating Average Price Target for Beta Bionics$22.56 High Price Target$30.00 Low Price Target$16.00 Potential Upside/Downside+32.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio14.68 Quick Ratio13.79 Sales & Book Value Annual Sales$65.12 million Price / Sales11.38 Cash FlowN/A Price / Cash FlowN/A Book Value$6.94 per share Price / Book2.46Miscellaneous Outstanding Shares43,470,000Free FloatN/AMarket Cap$741.16 million OptionableN/A BetaN/A The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BBNX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.